Oncternal Therapeutics In... (ONCT)
NASDAQ: ONCT
· Real-Time Price · USD
0.53
-0.16 (-23.63%)
At close: Dec 02, 2024, 10:00 PM
Oncternal Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | 801K | 569K | 297K | 179K | 106K | n/a | 171K | 382K | 191K | 746K | 556K | 2.13M | 883K | 748K |
Cost of Revenue | n/a | 5.9M | 6.06M | 6.67M | 75K | 37K | n/a | 35K | 35K | 65K | 44K | 3.7M | 8.96M | 5.19M | 3.91M |
Gross Profit | n/a | -5.1M | -5.49M | -6.37M | 104K | 69K | n/a | 136K | 347K | 126K | 702K | -3.14M | -6.83M | -4.31M | -3.17M |
Operating Income | -8.68M | -8.86M | -8.78M | -9.64M | -10.39M | -9.54M | -12.14M | -11.91M | -11.32M | -11.79M | -9.9M | -8.08M | -9.64M | -7.69M | -5.96M |
Interest Income | 217K | 304K | 391K | 472K | 528K | 579K | 656K | 515K | 200K | 54K | 8K | 7K | 7K | 8K | 11K |
Pretax Income | -8.46M | -8.56M | -8.39M | -9.16M | -9.86M | -8.97M | -11.49M | -11.4M | -11.13M | -11.74M | -9.9M | -8.07M | -9.63M | -7.68M | -5.95M |
Net Income | -8.46M | -8.56M | -8.39M | -9.16M | -9.86M | -8.97M | -11.49M | -10.88M | -10.72M | -11.63M | -9.89M | -8.07M | -9.63M | -7.68M | -5.95M |
Selling & General & Admin | 2.73M | 3.05M | 3.29M | 3.26M | 3.09M | 3.07M | 3.31M | 3.29M | 3.27M | 3.23M | 3.68M | 2.62M | 2.8M | 3.38M | 2.79M |
Research & Development | 6.45M | 6.61M | 6.06M | 6.67M | 7.47M | 6.58M | 9.03M | 8.8M | 8.44M | 8.76M | 6.98M | 6.02M | 8.96M | 5.19M | 3.91M |
Other Expenses | -494K | -5.9M | n/a | 203K | n/a | n/a | -203K | -171K | -382K | -191K | -746K | n/a | n/a | n/a | n/a |
Operating Expenses | 8.68M | 9.66M | 9.35M | 9.93M | 10.39M | 9.54M | 12.14M | 11.91M | 11.32M | 11.79M | 9.91M | 8.08M | 9.64M | 7.69M | 5.96M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 9.18M | 9.66M | 9.35M | 9.93M | 10.39M | 9.54M | 12.14M | 11.91M | 11.32M | 11.79M | 9.91M | 8.08M | 9.64M | 7.69M | 5.96M |
Income Tax Expense | n/a | n/a | n/a | n/a | -75K | -37K | n/a | -515K | -400K | -108K | -16K | -7K | -43K | -42K | -40K |
Shares Outstanding (Basic) | 2.96M | 2.96M | 2.96M | 2.95M | 2.95M | 2.94M | 2.93M | 2.83M | 16.11M | 16.11M | 16.11M | 16.11M | 16.11M | 16.11M | 16.11M |
Shares Outstanding (Diluted) | 2.96M | 2.96M | 2.96M | 2.95M | 2.95M | 2.94M | 2.93M | 2.83M | 16.11M | 16.11M | 16.11M | 16.11M | 16.11M | 16.11M | 16.11M |
EPS (Basic) | -2.86 | -2.89 | -2.83 | -3.11 | -3.35 | -3.05 | -3.93 | -3.85 | -0.67 | -0.72 | -0.61 | -0.5 | -0.6 | -0.48 | -0.37 |
EPS (Diluted) | -2.86 | -2.89 | -2.83 | -3.11 | -3.35 | -3.05 | -3.93 | -3.85 | -0.67 | -0.72 | -0.61 | -0.5 | -0.6 | -0.48 | -0.37 |
EBITDA | -8.68M | -8.86M | n/a | -9.19M | -10.39M | -9.54M | -12.14M | -12.13M | -11.32M | -11.79M | -9.91M | -8.08M | -9.64M | -7.69M | -5.96M |
EBIT | -8.68M | -8.86M | -8.78M | -9.64M | -10.39M | -9.54M | -12.14M | -11.91M | -11.32M | -11.79M | -9.91M | -8.08M | -9.64M | -7.69M | -5.96M |
Depreciation & Amortization | n/a | 8.86M | 8.78M | 9.64M | 75K | 37K | n/a | 35K | 35K | 65K | 44K | 44K | 43K | 42K | 40K |